Showing results (101-110 of 225) with videos related to
Sort By:
Pageof 23
Parasitology Research|February 25, 2012
Development of metronidazole-resistant lines of Blastocystis spL A Dunn, K S W Tan, P Vanelle, et al.Cancer Prevention Research (Philadelphia, Pa.)|January 28, 2010
Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse modelDanh Tran-Thanh, Stephen Buttars, Yanxia Wen, et al.Journal of the National Cancer Institute|May 3, 2001
p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breastS J Done, S Eskandarian, S Bull, et al.Journal of Clinical Pathology|January 24, 2019
Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advancesMiralem Mrkonjic, Hal K Berman, Susan J Done, et al.Breast Cancer Research and Treatment|March 23, 2001
P53 protein accumulation in non-invasive lesions surrounding p53 mutation positive invasive breast cancersS J Done, C R Arneson, H Ozçelik, et al.Breast Cancer Research : BCR|July 6, 2014
Validation of the prognostic gene portfolio, ClinicoMolecular Triad Classification, using an independent prospective breast cancer cohort and external patient populationsDong-Yu Wang, Susan J Done, David R Mc Cready, et al.Journal of Intellectual Disability Research : JIDR|May 10, 2002
Difficulties in conducting a randomized controlled trial of health service interventions in intellectual disability: implications for evidence-based practiceP C Oliver, J Piachaud, J Done, et al.Cancer Research|March 4, 1998
p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasiasS J Done, N C Arneson, H Ozçelik, et al.Schizophrenia Research|June 15, 2007
Do overinclusion and distorted semantic category boundaries in schizophrenia arise from executive dysfunction?V A Lawrence, O Doughty, A Al-Mousawi, et al.Nuclear Medicine and Biology|December 3, 2014
Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumabKaren Lam, Conrad Chan, Susan J Done, et al.Pageof 23